Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

被引：692

作者：

Sanacora, Gerard ^{[2
]}

Zarate, Carlos A. ^{[1
]}

Krystal, John H. ^{[2
]}

Manji, Husseini K. ^{[1
]}

机构：

[1] NIMH, Mol Pathophysiol Lab, Mood & Anxiety Disorders Res Program, NIH, Bethesda, MD 20892 USA

[2] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06510 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2008年 / 7卷 / 05期

关键词：

D O I：

10.1038/nrd2462

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.

引用

页码：426 / 437

页数：12

共 181 条

[61] Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate [J].

Hassel, B ;

Iversen, EG ;

Gjerstad, L ;

Tauboll, E .

JOURNAL OF NEUROCHEMISTRY, 2001, 77 (05) :1285-1292

[62] Astrocyte control of synaptic transmission and neurovascular coupling [J].

Haydon, Philip G. ;

Carmignoto, Giorgio .

PHYSIOLOGICAL REVIEWS, 2006, 86 (03) :1009-1031

[63] Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder [J].

Heresco-Levy, Uriel ;

Javitt, Daniel C. ;

Gelfin, Yovgenia ;

Gorelik, Elena ;

Bar, Marina ;

Blanaru, Monica ;

Kremer, Ilana .

JOURNAL OF AFFECTIVE DISORDERS, 2006, 93 (1-3) :239-243

[64] Localization of VGLUT3, the vesicular glutamate transporter type 3, in the rat brain [J].

Herzog, E ;

Gilchrist, J ;

Gras, C ;

Muzerelle, A ;

Ravassard, P ;

Giros, B ;

Gaspar, P ;

EL Mestikawy, S .

NEUROSCIENCE, 2004, 123 (04) :983-1002

[65] A novel action of lithium: Stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices [J].

Hokin, LE ;

Dixon, JF ;

Los, GV .

ADVANCES IN ENZYME REGULATION, VOL 36, 1996, 36 :229-244

[66] Disability and its treatment in bipolar disorder patients [J].

Huxley, Nancy ;

Baldessarini, Ross J. .

BIPOLAR DISORDERS, 2007, 9 (1-2) :183-196

[67] Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons [J].

Ivanov, Anton ;

Pellegrino, Christophe ;

Rama, Sylvain ;

Dumalska, Iryna ;

Salyha, Yuriy ;

Ben-Ari, Yehezkel ;

Medina, Igor .

JOURNAL OF PHYSIOLOGY-LONDON, 2006, 572 (03) :789-798

[68] Effects of riluzole on electrically evoked neurotransmitter release [J].

Jehle, T ;

Bauer, J ;

Blauth, E ;

Hummel, A ;

Darstein, M ;

Freiman, TM ;

Feuerstein, TJ .

BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (06) :1227-1234

[69] The long-term natural history of the weekly symptomatic status of bipolar I disorder [J].

Judd, LL ;

Akiskal, HS ;

Schettler, PJ ;

Endicott, J ;

Maser, J ;

Solomon, DA ;

Leon, AC ;

Rice, JA ;

Keller, MB .

ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (06) :530-537

[70] Valproic acid reduces enhanced vesicular glutamate transporter immunoreactivities in the dentate gyrus of the seizure prone gerbil [J].

Kang, TC ;

Kim, DS ;

Kwak, SE ;

Kim, JE ;

Kim, DW ;

Kang, JH ;

Won, MH ;

Kwon, OS ;

Choi, SY .

NEUROPHARMACOLOGY, 2005, 49 (06) :912-921

← 2 3 4 5 6 7 8 9 10 11 →